Multivariate Meta-Analyses of Antidepressants, Antipsychotics, Anxiolytics, Mood Stabilizers, Stimulants, Antidementia and Antiparkinsonian Drug Effects on Mitochondrial Complex I and IV in Rodent Models by Holper-Nellen, Lisa et al.
 This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=3235666 
                             Elsevier Editorial System(tm) for The Lancet 
Psychiatry 
                                  Manuscript Draft 
 
 
Manuscript Number: THELANCETPSYCH-D-18-00678 
 
Title: Multivariate meta-analyses of antidepressants, antipsychotics, 
anxiolytics, mood stabilizers, stimulants, antidementia and 
antiparkinsonian drug effects on mitochondrial complex I and IV in rodent 
models  
 
Article Type: Article (Meta-analysis) 
 
Keywords: meta-analysis; psychotropic drugs; NADH dehydrogenase; 
cytochrome-c-oxidase 
 
Corresponding Author: Dr. Lisa Holper,  
 
Corresponding Author's Institution: University Hospital of Psychiatry 
Zurich 
 
First Author: Lisa Holper 
 
Order of Authors: Lisa Holper; Dorit Ben-Shachar, Prof.; John J Mann, 
Prof. 
 
Manuscript Region of Origin: SWITZERLAND 
 
Abstract: Complex I (NADH dehydrogenase) and complex IV (cytochrome-c-
oxidase) of the mitochondrial electron transport chain are reported to be 
affected by drugs used to treat psychiatric or neurodegenerative 
diseases, including antidepressants, antipsychotics, anxiolytics, mood 
stabilizers, stimulants, antidementia and antiparkinsonian drugs. 
We conducted meta-analyses examining the effects of each drug category on 
complex I and IV. The electronic databases Pubmed, EMBASE, CENTRAL and 
Google Scholar were searched for studies published between 1970 and 2018. 
Of 3105 screened studies, 68 articles covering 53 drugs were included in 
the meta-analyses. All studies assessed complex I and IV in rodent brain 
at the level of enzyme activity.  
Meta-analyses revealed that selected antidepressants increase or decrease 
complex I and IV, antipsychotics and stimulants primarily decrease 
complex I but increase complex IV, whereas anxiolytics, mood stabilizers, 
antidementia and antiparkinsonian drugs preserve or even enhance both 
complex I and IV. To determine potential contributors to the drug 
effects, we meta-analyzed the drugs' neurotransmitter receptor profiles 
glutaminergic (NMDA1,3), histaminergic (H1), muscarinic (M1,3), opioid 
(OP1-3), serotonergic (5-HT2A, 5-HT2C, 5-
contributed most to the effects. We discuss the drug effects in relation 
to pharmacological mechanisms of action that might have relevance for 






This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=3235666




 1 of 39 
 
Multivariate meta-analyses of antidepressants, antipsychotics, anxiolytics, mood 
stabilizers, stimulants, antidementia and antiparkinsonian drug effects on mitochondrial 






, Ben-Shachar D 
2




 Department of Psychiatry, Psychotherapy, and Psychosomatics, University Hospital of Psychiatry 
Zurich, University of Zurich, Switzerland 
2
 Laboratory of Psychobiology, Department of Psychiatry, Rambam Health Care Campus, Rappaport 
Faculty of Medicine, Technion IIT, Haifa, Israel 
3
 Division of Molecular Imaging and Neuropathology, Columbia University and New York State 





Corresponding author: Lisa Holper, Department of Psychiatry, Psychotherapy, and Psychosomatics, 
University Hospital of Psychiatry Zurich, University of Zurich, 8032 Zurich, Switzerland, Phone: +41-
44-389 1576, Mail: holper@ini.phys.ethz.ch  
Manuscript
This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=3235666




 2 of 39 
 
Summary 
We conducted meta-analyses examining the effects of antidepressants, antipsychotics, anxiolytics, 
mood stabilizers, stimulants, antidementia and antiparkinsonian drugs on mitochondrial complex I and 
IV. The electronic databases Pubmed, EMBASE, CENTRAL, and Google Scholar were searched for 
studies published between 1970 and 2018. Results showed that antidepressants increase or decrease 
complex I and IV, antipsychotics and stimulants primarily decrease complex I but increase complex 
IV, whereas anxiolytics, mood stabilizers, antidementia, and antiparkinsonian drugs preserve or even 
enhance both complex I and IV. These effects could be related to the drugs’ neurotransmitter receptor 
profiles. We discuss the drug effects in relation to pharmacological mechanisms of action that might 
have relevance for clinical and research applications.  
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Abstract 
Background: Complex I (NADH dehydrogenase) and complex IV (cytochrome-c-oxidase) of the 
mitochondrial electron transport chain are reported to be affected by drugs used to treat psychiatric or 
neurodegenerative diseases, including antidepressants, antipsychotics, anxiolytics, mood stabilizers, 
stimulants, antidementia, and antiparkinsonian drugs. 
Methods: We conducted meta-analyses examining the effects of each drug category on complex I and 
IV. The electronic databases Pubmed, EMBASE, CENTRAL, and Google Scholar were searched for 
studies published between 1970 and 2018. Of 3105 screened studies, 68 articles covering 53 drugs 
were included in the meta-analyses. All studies assessed complex I and IV in rodent brain at the level 
of enzyme activity.  
Outcomes: Meta-analyses revealed that selected antidepressants increase or decrease complex I and 
IV, antipsychotics and stimulants primarily decrease complex I but increase complex IV, whereas 
anxiolytics, mood stabilizers, antidementia, and antiparkinsonian drugs preserve or even enhance both 
complex I and IV. To determine potential contributors to the drug effects, we meta-analyzed the 
drugs’ neurotransmitter receptor profiles and found that affinity to adrenergic (1B), dopaminergic 
(D1/2), glutaminergic (NMDA1,3), histaminergic (H1), muscarinic (M1,3), opioid (OP1-3), 
serotonergic (5-HT2A, 5-HT2C, 5-HT3A) and sigma (1) receptors contributed most to the effects.  
Interpretation: We discuss the drug effects in relation to pharmacological mechanisms of action that 
might have relevance for clinical and research applications.  
Funding: No specific funding.  
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Research in context 
Evidence before this study: Drugs used to treat psychiatric or neurodegenerative diseases, including 
antidepressants, antipsychotics, anxiolytics, mood stabilizers, stimulants, antidementia, and 
antiparkinsonian drugs are suggested to be one of the contributors to mitochondrial dysfunction 
observed in those disorders. Two enzymes have been shown to relate to mitochondrial function under 
those conditions, mitochondrial complex I (NADH dehydrogenase) and complex IV (cytochrome-c-
oxidase). We aimed to meta-analyze the effects of each drug category on complex I and IV. We 
conducted a structured literature search in PubMed, EMBASE, CENTRAL, and Google Scholar to 
identify studies published between January 1970 and May 2018 using the search strings ‘NADH 
dehydrogenase’ OR ‘cytochrome-c-oxidase’ OR ‘complex I’ OR ‘complex IV’ AND ‘antidepressants’ 
OR ‘antipsychotics’ OR ‘anxiolytics’ OR ‘mood stabilizers’ OR ‘stimulants’ OR ‘Alzheimer’ OR 
‘Parkinson’. Aggregated data were collected containing qualitative information (i.e., drug names, drug 
mechanisms of action, and brain regions of interest (ROIs)), quantitative data (i.e., number of drug-
administered and control animals, dosage, and duration of drug administration), and outcomes (effect 
sizes in terms of standardized mean differences (SMD) and p-values). 
Added value of this study: This meta-analysis summarizes the findings of drugs used to treat 
psychiatric and neurodegenerative disorders with regard to their effects on mitochondrial complex I 
and IV and relates those findings to the drugs’ neurotransmitter receptor profiles. 
Implications of all the available evidence: Combined with existing evidence, the results of the meta-
analysis may guide researchers and clinicals in the use of drugs to treat psychiatric and 
neurodegenerative disorders to consider how psychopharmacological agents and their neurotransmitter 
receptors profiles interact on mitochondrial function. Considering those relationships may help to 
reduce the burden of mitochondrial dysfunction in psychiatric and neurodegenerative conditions.  
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Introduction 
Impaired mitochondrial function is linked to the pathophysiology of major psychiatric disorders such 
as mood disorders and schizophrenia
1–4
 and neurodegenerative disorders such as Alzheimer’s and 
Parkinson’s.
5
 Mitochondrial function is essential for production of adenosine triphosphate (ATP), the 
main source of cellular energy. Impaired mitochondrial function results in decreased energy 
metabolism, reduced bioenergetics, oxidative stress, and apoptosis.
3
 
Psychotropic medication used to treat psychiatric or neurodegenerative conditions may target 
mitochondrial dysfunction.
6–8
 For instance, psychiatric drugs such as antidepressants are thought to 
inhibit mitochondrial respiration leading to decreased ATP production in animal models of 
depression.
9
 Both typical and atypical antipsychotics impair mitochondrial function by inducing 
structural gene changes also implicated in depletion of ATP supply.
10
 Anxiolytics such as 
benzodiazepines
7
 and stimulants such as amphetamines
11
 weaken mitochondrial function through the 
formation of free radicals, particularly reactive oxygen species. Conversely, mood stabilizers such as 
lithium or valproic acid have been shown to preserve or even enhance mitochondrial function by 
increasing the rate of cellular respiration.
10
 Similarly, medication to treat neurodegenerative disorders, 
for example antidementia drugs such as cholinesterase inhibitors (ChEIs) or antiparkinsonian drugs 
such as the dopamine agonist levodopa
12
 or monoamine oxidase inhibitors (MAOIs),
13
 may have 
neuroprotective effects that restore and maintain mitochondrial function. Together, these effects may 
contribute to both adverse effects and efficacy of many psychotropic medications, not only in patients 
with mitochondrial disorders but also in the much wider population receiving these agents for 
psychiatric or neurodegenerative illnesses
14
 as we have discussed in our previous meta-analysis.
15
 
Prior to ATP generation, mitochondria direct electrons extracted from nutrients into a transmembrane 
proton gradient and this process is mediated by the electron transport chain (ETC). Two enzymes of 
the ETC located at the inner mitochondrial membrane are the most impaired in psychiatric and 
neurodegenerative disorders based on our recent meta-analysis
15
 and the most affected ETC enzymes 
by psychotropic drugs.
16
 The first enzyme, complex I (NADH dehydrogenase, NDU), is one of the 
entry enzymes of cellular respiration or oxidative phosphorylation in the mitochondrion. NDU is the 
largest multimeric ETC complex and a major contributor to the proton gradient across the 
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mitochondrial inner membrane, which drives ATP production. The second enzyme of interest, 
complex IV (cytochrome-c-oxidase, COX), catalyzes the final step in the ETC. Due to its rate-limiting 
role in this oxidative process
17
 and its coupling with neuronal activation,
18,19
 COX is proposed as a key 
marker of mitochondrial as well as neuronal function.
20
 The two enzymes interact in that an assembled 
complex IV is required to maintain the stability of complex I 
21–23
. Both complex I and IV also 
represent clinically relevant targets due to their accessibility using novel in-vivo technologies assessing 
complex I redox states
24,25
 or oxidized complex IV.
26
 
We chose the seven drug categories of antidepressants, antipsychotics, anxiolytics, mood stabilizers, 
stimulants, antidementia, and antiparkinsonian drugs, not only because of their potential common 
effects on mitochondrial function, but also based on the overlapping indications for which they are 
used to treat in clinical practice. Antidepressants are used in mood and anxiety disorders, but are also 
frequently applied to treat depressive symptomatology in schizophrenia and both Alzheimer’s and 
Parkinson’s.
27,28
 Antipsychotics are used in schizophrenia as well as mood disorders to ameliorate 
psychotic episodes and used as antidepressants and anti-manic treatment.
29
 Mood stabilizers are 
typically used for recurrent mood disorders but atypical antipsychotics can also be beneficial in 
schizophrenia due to their anti-aggressive effects
30
 and possible improvement of negative symptoms.
31
 
Anxiolytics and stimulants are commonly given alone or in combination with antidepressants to treat 
comorbid anxiety,
32
 fatigue, or attention deficits.
33,34
 Antidementia drugs are not only used in 




 to treat 
comorbid dementia symptoms. 
Besides the overlap in clinical application, the seven drug categories also show similarities in their 
mechanisms of action and neurotransmitter receptor and transporter binding profiles. Antidepressants, 
such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors 
(SNRIs), or norepinephrine and dopamine reuptake inhibitors (NDRIs), primarily increase the levels 
of the monoamine neurotransmitters serotonin (5-hydroxytryptamine, 5-HT), norepinephrine, and 
dopamine (D) by inhibiting their reuptake at the corresponding transporters (SERT, NET, DAT);
37–42
 
to a lesser extent, some antidepressants also interact with adrenergic (,), glutaminergic (-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid, AMPA, N-methyl-D-aspartate, NMDA), histaminergic 
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(H), muscarinic (M), melatonergic (MT), and sigma () receptors. Typical antipsychotics exert their 
clinical effects as D2 receptor antagonists as their common target
43,44
 and 5-HT2A receptor antagonists 
for atypical antipsychotics.
45
 Occupancy of other 5-HT receptors and , H, M receptors contributes to 
side effects and adverse effects.
46–48
 Anxiolytics such as benzodiazepines exert their various effects 
through allosteric modulation of gamma-aminobutyric acid (GABA-A) receptor.
49
 Stimulants work by 
releasing dopamine and also have a moderate affinity for monoamine transporters (SERT, NET, 
DAT)
50,51
 and to a lesser extent  and D receptors.
52
 Similarly, antidementia drugs such as 
cholinesterase inhibitors (ChEIs) and antiparkinsonian drugs such as the dopamine agonist levodopa 
target D receptors, inhibit acetylcholine (ACh) catabolism and have down-stream effects on 5-HT, , 
DAT and NMDA receptors.
53
 These and other receptors have been shown to affect mitochondrial 





 have discussed the detailed effects on complex I and IV caused by 
each of the above-mentioned drug categories. A meta-analysis summarizing the findings across these 
drugs cannot be found in the literature. We conducted a literature review, screening for suitable papers 
and then conducted a meta-analysis examining the effects of each drug category on complex I and IV. 
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Materials and methods  
Literature search and study identification 
We conducted a structured literature search in PubMed, EMBASE, CENTRAL, and Google Scholar to 
identify studies published between January 1970 and May 2018 using the search strings ‘NADH 
dehydrogenase’ OR ‘cytochrome-c-oxidase’ OR ‘complex I’ OR ‘complex IV’ AND ‘antidepressants’ 
OR ‘antipsychotics’ OR ‘anxiolytics’ OR ‘mood stabilizers’ OR ‘stimulants’ OR ‘Alzheimer’ OR 
‘Parkinson’. We additionally manually reviewed reference lists in all retrieved articles for related 
publications. Inclusion criteria were: studies published in the English language, studies investigated 
complex I and/or complex IV, studies reporting data in rodent disease models in comparison with a 
control group. Exclusion criteria were: studies in human patient populations, studies in other tissues 
than brain tissue, cellular studies, genetic studies, case reports, and publications not reporting original 
data. 
Data extraction  
Aggregated data were extracted for each of the seven drugs categories: antidepressants, antipsychotics, 
anxiolytics, mood stabilizers, stimulants, antidementia, and antiparkinsonian drugs. Aggregated data 
contained qualitative information (i.e., drug names, drug mechanisms of action, and brain regions of 
interest (ROIs)), quantitative data (i.e., number of drug-administered and control animals, dosage, and 
duration of drug administration), and outcomes (effect sizes in terms of standardized mean differences 
(SMD) and p-values). In case of aggregated data not presented in the text, the authors were contacted 
for permission to reuse original data or data were read from figures. Mechanisms of action and 
receptor affinity profiles of each drugs were derived from DrugBank,
56
 when available.  
Multivariate random-effect meta-analyses  
Three separate meta-analyses were computed for complex I and IV separately to estimate: 1) the 
effects of drugs; 2) the effects of mechanisms of action; and 3) the effects of receptor affinity.  
Moderators were built for each meta-analysis. ‘Drug’ moderators were based on the International 
Nonproprietary Names (INN) of the corresponding active pharmaceutical ingredients (e.g., 
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‘escitalopram’ for cipralex). ‘Mechanism of action’ moderators were built by categorizing each drug 
according to its corresponding primary drug mechanism (e.g., ‘escitalopram’ was categorized as 
‘SSRI’); drugs with unknown mechanisms of action were categorized according to their therapeutic 
uses (e.g., ‘valproic acid’ was categorized as ‘antiepileptic drug (AEG)’). ‘Receptor affinity’ 
moderators were built by assigning each drug to its corresponding affinity for one or more of the 
various neurotransmitter receptors, transporters, or enzymes,
56
 if available. The type of receptor 
binding, i.e., agonism or antagonism (coded 1 and -1), was treated as a covariate. Not considered was 
binding affinity (i.e., the inhibitory constant, Ki), since it is not available for all drugs.  
All meta-analyses were performed using a multivariate, random-effect model based on the Metafor 
package
57
 as implemented in R.
58
 The multivariate model accounted for heterogeneity and dependency 
in the underlying true effects of multiple moderators that could overlap within subjects and studies 
(random factors). To adjust for dosage (mg/day) and administration duration (days) of the specific 
drugs, categorical dummy covariates were used. To adjust for sample size, effects were weighted 
based on study size. To allow for heterogeneity differences between moderators, an unstructured 
variance-covariance matrix was applied (function rma.mv; observed effects = SMD + dosage + 
duration; variance-covariance matrix = COV; weight = study size; variance structure = UN; 
moderators = ‘drugs’ OR ‘mechanism of action’ OR ‘receptor affinity : type’; random factors = 
subject + study; method = REML). A Wald-type test
57
 was used to compare subgroup estimates 
between complex I and IV. 
Heterogeneity was assessed using Cochran's Q-test and the inconsistency I
2
 statistic that directly 
indicates to what extent each outcome contributes to the total variance. Publication bias was assessed 
using Egger’s regression analysis.   
This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=3235666








Of 3105 screened studies, 68 studies were eligible for the meta-analyses (Tab. 1, Dataset S1) on 
antidepressants (AD), antipsychotics (AP), anxiolytics (AX), mood stabilizers (MS), stimulants (ST), 
antidementia drugs (ADD), and antiparkinsonian drugs (APD). In total, studies covered 53 drugs (AD 
N = 18, AP N = 10, AX N = 3, MS N = 5, ST N = 4, ADD N = 7, APD N = 7). The number of studies 
reporting on complex I (total N = 72, AD N = 24, AP N = 10, AX N = 4, MS N = 10, ST N = 9, ADD 
N = 6, APD N = 9) and complex IV (total N = 62, AD N = 26, AP N = 9, AX N = 3, MS N = 10, ST N 
= 6, ADD N = 5, APD N = 3) varied between drug categories, some of them reporting the same drug 
in more than one drug category. All studies analysed complex I and IV at the level of enzymatic 
activity in brain tissue from rodents (rats or mice) decapitated after drug administration. No eligible 
studies were found in healthy human brain tissue. Complex I and IV were analysed either in selected 
ROIs (AD N = 24, AP N = 7, AX N = 2, MS N = 9, ST N = 8, ADD N = 4, APD N = 7) and/or in 
brain homogenates (AD N = 14, AP N = 9, AX N = 2, MS N = 3, ST N = 5, ADD N = 4, APD N = 2). 
Drugs were investigated in one/two or more dosage steps (AD N = 18/10, AP N = 6/6, AX N = 3/1, 
MS N = 9/2, ST N = 5/4, ADD N = 4/2, APD N = 8/1). Mean (range) duration of drug administration 
was similar between drug categories (AD = 11 (1-28) days; AP = 17 (1-90) days; AX = 12 (1-30) 
days; MS = 14 (1-42) days; ST = 12 (1-28) days; ADD = 9 (1-21) days; APD = 5 (1-60) days). Mean 
number of animals per study (i.e., sum of drug-administered animals plus control animals) was also 
similar between drug categories (AD N = 14, AP N = 11, AX N = 21, MS N = 13, ST N = 13, ADD N 
= 15, APD N = 11). Control animals received saline or were sham groups in diseases models. 
Considering all above-mentioned factors, drug category, enzymes, selected ROIs, dosage, and 
administration duration, 1215 data points were extracted. Mechanisms of action and receptor affinity 
profiles collected based on previous work
56
 are provided in Tab. 1, Fig. S1, Dataset S2.  
Multivariate random-effect meta-analyses  
Meta-analyses assessed complex I and IV enzyme activity regarding the 1) effects of drugs (Fig. 1), 2) 
effects of mechanisms of action (Fig. 2), and 3) effects of receptor affinity (Fig. 3).  
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Drugs  
Antidepressants had negative effects on complex I for desipramine (p = 0026) and escitalopram (p < 
00001), whereas positive effects were observed for agomelatine (p = 000017), paroxetine (p = 0034), 
and sertraline (p < 00001) consistent with decreased versus increased NDU enzyme activity. Negative 
effects on complex IV were found for amitriptyline (p = 0023), desipramine (p < 00001), fluoxetine 
(p = 0045), fluvoxamine (p < 00001) and mirtazapine (p = 0046), whereas positive effects were 
observed for ketamine (p = 000021), nortriptyline (p < 00001), trazodone (p = 00014), and sertraline 
(p = 0023). Differences in drug effects between complex I and IV were observed for agomelatine (p = 
00003), escitalopram (p < 00001), paroxetine (p = 0048), and sertraline (p = 0023) as assessed using 
a Wild-type test.   
Antipsychotics that had negative effects on complex I included chlorpromazine (p < 00001), 
thiothixene (p = 000012), and haloperidol (p < 00001) consistent with decreased NDU enzyme 
activity. By contrast, positive effects on complex IV were observed for haloperidol (p = 0039) and 
risperidone (p = 000023) indicating increased COX enzyme activity. All drug effects were 
significantly different between complex I and IV (chlorpromazine p < 00001, haloperidol p < 00001, 
risperidone p = 0023, thiothixene p = 0001) as assessed using a Wild-type test.   
Anxiolytics had a positive effect on complex IV for diazepam (p = 00014), and no detectable effects 
were found on complex I. 
Mood stabilizers had a positive effect on complex I for lithium (p = 002) and on complex IV for 
gabapentin (p = 0047).  
Stimulants having negative effects on complex I included amphetamine (p = 00099), mazindol (p < 
00001), methamphetamine (p = 00012), and methylphenidate (p < 00001). There were no significant 
effects on complex IV.  
Antidementia drugs having positive effects on complex IV included memantine (p = 0034) and 
latrepirdine (p = 0029). There were no significant effects on complex I. 
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Antiparkinsonian drugs having a positive effects on both complex I and complex IV were limited to 
selegiline (p = 0013 and p = 00033, respectively), without significant differences between complex I 
and IV effects.  
Mechanisms of action  
Categorizing drugs according to their mechanisms of action revealed only few relevant findings 
compared to the abovementioned analysis. Negative effects on complex I were observed for typical 
antipsychotics (p < 00001; Wild-type test p < 00001), whereas lithium (p = 0018) and NDDIs (p = 
001; Wild-type test p = 0025) had positive effects. Positive effects on complex IV were also found 
for both AEGs (p = 0046) and NMDA antagonists (p = 00024) (Fig. 2).  
Receptor affinity 
Receptor affinity profiles were available for 45 drugs
56
 (out of 56 drugs) (antidepressants N = 17 (out 
of 18 drugs), antipsychotics N = 10 (out of 10 drugs), anxiolytics N = 2 (out of 3 drugs), mood 
stabilizers N = 4 (out of 5 drugs), stimulants N = 4 (out of 4 drugs), antidementia drugs N = 4 (out of 7 
drugs), antiparkinsonian drugs N = 4 (out of 7 drugs)) (Fig. S1, Dataset S2). The results shown in Fig. 
3 thus represent information derived from combinations of drugs that share high affinity for a specific 
receptor but may differ in their affinity for other receptors.  
For complex I, negative effects were found for 5-HT2A (p = 00044), 1B (p = 0027), D1 (p = 
000013), D2 (p = 00021), H1 (p = 0022), M1 (p = 0017), and M3 (p = 0024), whereas positive 
effects were observed for 1 (p < 00001). For complex IV, negative effects were found for 5-HT3A (p 
= 0035), DAT (p = 00035), and NET (p = 0014), whereas positive effects were observed for 5-HT2C 
(p = 0022), NMDA1,3 (p = 000012), OP1 (p = 00018), OP2 (p = 00056), OP3 (p = 0016), and 1 
(p = 0021). Differences in receptor effects on complex I and IV were found for 5-HT2A (p = 0003), 
1A (p = 0021), 1B (p = 0021), D1 (p = 00002), D2 (p = 0014), H1 (p = 0026), M1 (p = 0045), 
NMDA1,3 (p = 0003), and 1 (p = 0009) as assessed using a Wild-type test. 
None of abovementioned meta-analyses revealed relevant interaction effects with selected ROIs and 
we therefore do not report the corresponding results. 
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Heterogeneity and publication bias 
Overall, there was a high degree of heterogeneity as indicated by significant Q-statistics (p < 005) and 
large I
2
 values (Tab. 2). Putative low heterogeneity was observed for stimulants in complex I (Q = 
4593, p = 0434, I
2
 = 11%), anxiolytics in complex IV (Q = 457, p = 0102, I
2
 = 82%), and 
antiparkinsonian drugs in complex IV (Q = 558, p = 0589, I
2
 = 34%), perhaps explained by the small 
study numbers in those drug categories (Tab. 1). Publication bias as assessed using Egger’s regression 
test (Tab. 2) revealed non-significant results for all drug categories indicating no relevant publication 
bias.  
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Discussion  
This meta-analysis finds many drugs used to treat psychiatric and neurodegenerative disorders to 
affect mitochondrial complex I and IV. Overall antidepressants show the most heterogenous effects on 
complex I and IV with some exhibiting negative effects while others have positive effects. 
Antipsychotics and stimulants primarily decrease complex I but increase complex IV. By contrast, 
anxiolytics, mood stabilizers, antidementia, and antiparkinsonian drugs affect both complex I and IV 
positively. To narrow down potential contributors to the drug effects, we meta-analysed mechanisms 
of action and receptor profiles and found that antagonism of adrenergic (1B), dopaminergic (D1,2), 
histaminergic (H1), muscarinic (M1,3) and serotonergic (5-HT2A) receptors result in negative effects 
on complex I, whereas agonism of sigma (1) receptors increases complex I. By contrast, antagonism 
of serotonergic (5-HT3A) receptors as well as inhibition of DAT and NET are associated with 
decreases in complex IV, whereas antagonism of glutaminergic (NMDA1,3) and serotonergic (5-
HT2C) receptors as well as agonism of opioid (OP1-3) and sigma (1) receptors results in positive 
effects on complex IV. These findings support a relationship between drug effects and receptor 
affinity profiles and mitochondrial complex I and IV, which may have relevance for selection of 
treatment with low mitochondrial toxic potential in psychiatric and neurodegenerative conditions as 




Antidepressants have heterogenous effects on complex I and IV independent of their canonical 
mechanisms of action (Fig. 1 & 2). For example, while some SSRIs exhibit negative effects such as 
escitalopram on complex I
59
 or fluoxetine and fluvoxamine on complex IV,
60–64
 other SSRIs have 
positive effects such as paroxetine on complex I
65,66
 and sertraline on both complex I and IV.
67,68
 
Similarly, some norepinephrine reuptake inhibitors (NRIs) such as desipramine and amitriptyline 
reveal strong negative effects on complex I and/or IV,
16,64,69
 whereas nortriptyline, another NRI, 
affects complex IV positively.
66
 Noradrenergic and specific serotonergic antidepressants (NaSSAs) 
such as mirtazapine have negative effects on complex IV (and I),
16
 while serotonin antagonists and 
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reuptake inhibitors (SARIs) such as trazodone were observed to have a positive effect on complex 
IV.
68
 The heterogeneity of these effects is likely related to the broader receptor profile of 
antidepressants such as antagonizing or agonizing adrenergic, dopaminergic, histaminergic, 
muscarinic, opioid, serotonergic and sigma receptors and inhibiting DAT, NET and SERT 
transporters. The combination of those receptor profiles in different antidepressants may lead to 
opposite effects on complex I and IV (Fig. 3). For example, antagonism of most serotonergic, i.e., 5-
HT1A, 5- HT2A/C, 5-HT3, receptors has previously been shown to inhibit complex I, mitochondrial 




 and cardiac 
mitochondria,
73
 respectively, in line with our findings (Fig. 3). Similarly, antagonism of muscarinic 
(M)
74
 and histaminergic, especially H3 brain-specific receptors,
75
 inhibits natural mitochondrial 
protection from apoptotic and oxidative stress, the latter potentially antagonizing neuroprotective 
NMDA receptor activation.
76




 receptors can inhibit 
mitochondrial function by blocking their role in the stimulation of mitochondrial biogenesis (Fig. 3). 
By contrast, opioid receptors, especially delta-opioid receptors (OP1) (Fig. 3), are neuroprotective, 
particularly in cerebral cortex, by stabilizing ionic homeostasis, increasing antioxidant capacity and 
attenuating disrupted neuronal transmission.
80,81
 Also, sigma () receptor agonism, especially 1 





1-ligands are thus discussed as protein-based pharmacological treatment to treat mitochondrial 
dysfunction in psychiatric and neurodegenerative conditions.
83
 
Notably, agomelatine, a norepinephrine and dopamine disinhibitor (NDDI) and melatonergic MT1/2 
agonist, was found to have a prominent positive effect on complex I in this meta-analysis (Fig. 1 & 2). 
Previous work showed that low-dose agomelatine increases complex I activity in prefrontal cortex, 
cerebellum, and striatum, while decreasing it in the posterior cortex, whereas high-dose agomelatine 
decreases complex I activity in all those brain regions.
84
 Agomelatine is thought to protect against 
pathology-induced decreases in complex I
85–87





 and inhibiting the opening of mitochondrial permeability transition pores.
89
 This effect 
may be mediated by its agonist action at MT1 and MT2 receptors that have antioxidant activity and 
free radical scavenging, both actions are therapeutic for oxidative stress.
90
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Ketamine, a NMDA receptor antagonist, used as rapidly acting antidepressant,
91
 was found to have a 
positive effect on complex IV (and to some extent complex I)
92–95
 (Fig. 1 & 2). Previous work showed 
that ketamine increases complex IV but not complex I activity.
93
 In the short-term (1 hour after 
treatment) it has been shown to increase complex IV activity in striatum and hippocampus but not in 
prefrontal cortex, whereas more delayed responses (after 6 hours of treatment) were described only in 
striatum.
92
 Ketamine also increases other enzymes such as peroxiredoxins that enhance cellular 
antioxidant capacity by combating reactive oxygen species, reducing protein damage and adjusting 
homeostatic redox, which supports the role of mitochondria as downstream effectors mediating its 
rapid antidepressant action.
96
 Ketamine’s effects on complex IV may be reflected in the strong positive 
effects of the ionotropic glutamatergic NMDA receptor (Fig. 3) that is co-regulated by the same 
transcription factors as COX
18,19




Antipsychotics show strong negative effects on complex I primarily accounted for by the typical 
antipsychotics, chlorpromazine, thiothixene, and haloperidol
98–104
 (Fig. 1 & 2). Antagonism of 
dopaminergic, primarily D2, receptors by typical antipsychotics (Fig. 3) may lead to dopamine 
accumulation in mitochondria resulting in D2-induced inhibition of complex I,
105,106
 which in turn has 
been associated with the induction of extrapyramidal side effects (EPS).
101,107
 By contrast, haloperidol 
affects complex IV positively
102
 as supported by our analysis (Fig. 1). These opposing haloperidol 
effects on complex I and IV are thought to result from either up-stream (D2-induced) inhibition of 
complex I in the ETC
21–23
 or reflect (D2-independent) enhanced functional neuronal activation due to 
the coupling between COX and neuronal activity.
19
 This in turn may be clinically reflected in the 
delayed therapeutic effects of neuroleptic agents.
102
 
By contrast, atypical antipsychotics were observed to have no significant effects besides an isolated 
increase in complex IV by risperidone
65,98,99
 (Fig. 1), which might be related to their lower D2 receptor 
affinity for serotonergic 5-HT2A,
108
 adrenergic, muscarinic, and histaminic receptors,
44,109
 which also 
implies lower rates of EPS. 
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Together, these results support a complex I participation in dopamine-induced mitochondrial 
dysfunction such as observed in postmortem brain samples from deceased schizophrenic patients,
110–
115
 whereas the reduction in COX activity observed in schizophrenia
15,116





Evidence that anxiolytics have weak positive effects on complex IV, is not certain because of the 
small number of studies in this drug category. Only the benzodiazepine, diazepam, a GABA-A 
receptor positive allosteric modulator (PAM) (Fig. 2), enhanced complex IV (Fig. 1), suggesting that 
this GABA-A effect may not be the mechanism because all the other benzodiazepines do not have this 
effect on complex IV. The possibility of an effect of GABA-A receptors (Fig. 3) was thus not 
supported by our analysis but needs to be further evaluated when more subjects have been studied 
because of the known neuroprotective effects of GABA-A agonists that may preserve COX activity by 





Mood stabilizers show positive effects on both complex I and IV. Lithium, the most established mood 
stabilizer, increases complex I
16,119–124
 (Fig. 1 & 2) by acting on intracellular Ca
2+
 signaling, inhibiting 
inositol monophosphatase,
4
 and modulating the neuroprotective ionotropic glutamatergic AMPA 
receptor,
125–128
 which, however, did not reach significance in our analysis (Fig. 3). These findings are 
consistent with human studies in postmortem brain of patients with bipolar depression that report 




Antiepileptics, also used as mood stabilizers, such as gabapentin, enhance complex IV
131,132
 (Fig. 1 & 
2), which may be related to their NMDA receptors antagonism
133
 since it showed positive effects for 
other drugs as well (Fig. 3). The main action of AEDs is to increase GABA transmission, which did 
show effects (Fig. 3). Although, little is known about the impact of AEDs on mitochondria, our 
findings suggest that some AEDs like gabapentin and lamotrigine) have beneficial effects despite 
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Stimulants such as amphetamine, methamphetamine, mazindol and methylphenidate, all dopamine 
reuptake inhibitors (DRIs), affect complex I negatively
135–143
 (Fig. 1 & 2) potentially related to their 
inhibition of DAT, NET and SERT transporters
144
 (Fig. 3). Amphetamine enters and accumulates in 
mitochondria thereby dissipating the electrochemical gradient established by the ETC, inhibiting 
complex I and releasing cytochrome c, which in turn may induce the aforementioned interaction with 




Antidementia drugs have no effects on complex I and it is not clear whether they affect complex IV 
(Fig. 1 & 2). Cholinesterase inhibitors (ChEIs), the most established antidementia drugs, inhibit ACh 
catabolism leading to its accumulation, greater stimulation of nicotinic and muscarinic receptors, and 
disrupted neurotransmission that may explain some of their positive effects on learning, memory, and 
other cognitive functions in Alzheimer’s.
146
 Memantine, a NMDA antagonist, also has a positive effect 
on complex IV
147–149
 (Fig. 1 & 2) reflected in the strong positive NMDA receptor effect (Fig. 3) that is 
thought to restore unbalanced homeostasis in the glutamatergic system.
150
 Positive effects on complex 
IV were also observed for latrepirdine
149
 (Fig. 1); however, since its mechanism of action is not fully 
known its receptor affinity profile could not be assessed in the present analysis,
56
 but may include 
neuroprotective effects by blocking neurotoxic Alzheimer beta-amyloid via modulation of NMDA 
receptors.
151,152
 Together, these findings suggest that the well-documented deficit in complex IV in 
Alzheimer’s,
5,153,154
 thought to be due to neuronal toxicity and hypometabolism induced by beta-
amyloid accumulation in mitochondria
155–158
 can be addressed with antidementia drugs. 
Antiparkinsonian drugs 
The most established antiparkinsonian drug, levodopa, an indirect dopamine agonist, was not found to 
affect complex I or IV.
159–163
 This is in contrast to previous findings stating that levodopa significantly 
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increases complex I activity, while not changing complex IV activity
161
 or that levodopa does not alter 
complex I activity by itself, but attenuates the decrease in complex I activity induced by MPTP (1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine), the prodrug to the neurotoxin MPP
+
 (1-methyl-4-
phenylpyridinium) which causes permanent symptoms of Parkinson's disease by destroying 
dopaminergic neurons in the substantia nigra.
159
 
However, a weak positive effect on both complex I and IV was observed for selegiline, a selective 
irreversible MAO-B inhibitor in lower doses
164
 (Fig. 1 & 2). Selegiline is thought to be 
neuroprotective by suppressing Ca
2+
 efflux through mitochondrial permeability transition pores 
thereby inducing anti-apoptotic, pro-survival genes, though this is disputed.
165
 Selegiline could thus 
protect mitochondrial function when used to treat Parkinson's symptoms in combination with 
levodopa,
166
 but also off-label as palliative treatment for Alzheimer's dementia
167
 and, as part of its 




The present meta-analysis focused on rodent studies since no eligible studies were found in healthy 
human brain tissue. Doses and tissue levels of the cited drugs achieved in rodents are often much 
higher than those achieved in clinical treatment in humans. This is usually done to maximize effect but 
may create effects that are not clinically relevant. Such high doses may therefore have direct effects on 
mitochondrial electron transport, which may not be directly translatable to the effects expected at 
corresponding human doses. Further, we focused on drug effects at the neurotransmitter receptors 
level, but that is only one way drugs may indirectly alter mitochondrial activity. The observed 
considerable heterogeneity therefore needs to be considered indicating that not all effects can be 
explained at neurotransmitter receptors level. As an aside, the associations observed here are just 
"associations", they do not imply causality.  
Conclusion 
Summarizing the overall strength of mitochondrial changes caused by the seven drug categories 
indicates that antidepressants have the most heterogenous effects on both complex I and IV, which 
may be attributed to their broad receptor profiles including affinity to adrenergic (), histaminergic 
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(H1-4), muscarinic (M1-5), opioid (OP1-3), serotonergic (5-HT2A, 5-HT2C, 5-HT3A), and sigma (1) 
receptors. Typical versus atypical antipsychotics show strong negative effects on complex I versus 
weaker or no positive effects on complex IV, most likely associated with differential affinity for 
dopaminergic (D2), and serotonergic (5-HT2A) receptors. Stimulants also exhibit strong negative 
effects on complex I, potentially related to their inhibition of DAT, NET, and SERT transporters. Why 
stimulants and typical antipsychotics share a negative effect on complex I is hard to relate to the 
worsening of positive symptoms of psychosis by stimulants and the improvement by antipsychotics. In 
contrast, positive effects on complex I and/or IV are observed for anxiolytics, mood stabilizers, 
antidementia, and antiparkinsonian drugs, potentially associated with GABAergic (GABA-A), 
glutamatergic (AMPA, NMDA), and nicotinic (nACh) receptor effects. Further research is required, to 
better understand the connection between the actions of therapeutic agents and mitochondrial 
complexes. This may contribute to the development of mitochondrial targeted treatments in 
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Fig. 1. Forest plot: Drugs. Multivariate estimates of the effects (SMD, 95% CI, p-values) of 
antidepressants, antipsychotics, anxiolytics, mood stabilizers, stimulants, antidementia drugs and 
antiparkinsonian drugs on complex I and IV enzyme activities. Values lower than 0 indicate that 
treated animals had lower levels than controls, and vice versa for values greater than 0; the dashed 
vertical line at SMD = 0 indicates no effect. The size of the filled circles for each estimated SMD is 
proportional to the weight of the studies.  
 
Fig. 2. Forest plot: Mechanism of action. Multivariate estimates of the effects (SMD, 95% CI, p-
values) on complex I and IV enzyme activities of mechanisms of action of antidepressants, 
antipsychotics, anxiolytics, mood stabilizers, stimulants, antidementia drugs and antiparkinsonian 
drugs. Values lower than 0 indicate that animals treated had lower levels than controls, and vice versa 
for values greater than 0; the dashed vertical line at SMD = 0 indicates no effect. The size of the filled 
circles for each estimated SMD is proportional to the weight of the studies. 
Antipsychotics (APs), antiepileptic drugs (AEGs), cholinesterase inhibitors (ChEIs), dopamine agonists (DAGs), dopamine 
reuptake inhibitors (DRIs), gamma-aminobutyric acid (GABA)A receptor positive allosteric modulators (PAMs), monoamine 
oxidase inhibitors (MAOIs), muscarinic M1 agonists (M1 AGs), N-methyl-D-aspartate receptor antagonists (NMDA ANTs), 
noradrenergic and specific serotonergic antidepressants (NaSSAs), norepinephrine-dopamine disinhibitors (NDDIs), 
norepinephrine–dopamine reuptake inhibitors (NDRIs), norepinephrine reuptake inhibitors (NRIs), reversible inhibitors of 
monoamine oxidase A (RIMAs), serotonin antagonist and reuptake inhibitors (SARIs), serotonin–norepinephrine reuptake 
inhibitors (SNRIs), selective serotonin reuptake enhancers (SSREs), selective serotonin reuptake inhibitors (SSRIs). 
 
Fig. 3. Forest Plot: Receptor affinity. Multivariate estimates of the effects (SMD, 95% CI, p-values) 
on complex I and IV enzyme activities by receptor affinity of antidepressants, antipsychotics, 
anxiolytics, mood stabilizers, stimulants, antidementia drugs and antiparkinsonian drugs. Values lower 
than 0 indicate that animals treated had lower levels than controls, and vice versa for values greater 
than 0; the dashed vertical line at SMD = 0 indicates no effect. The size of the filled circles for each 
estimated SMD is proportional to the weight of the studies. Type of receptor binding, i.e., agonism 
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(AG) or antagonism (ANT), is indicated. See Fig. S1, Dataset S2 for included drugs and affinity 
profiles. 
Adrenergic (,), dopaminergic (D), GABAergic (GABA-A), glutaminergic (NMDA, AMPA), histaminergic (H), 
muscarinic (M), nicotinic (nACh), opioid (OP), serotonergic (5-HT), sigma (). DAT, NET and SERT correspond to the 
abilities of the drugs to inhibit the reuptake of dopamine, norepinephrine and serotonin, respectively.  
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Tab. 1. Eligible studies. 68 studies were eligible for the meta-analyses covering 53 drugs. Mechanisms of actions are indicated 
56
. Some studies reported more 
than one drug. The detailed data extracted from these studies are provided in Dataset S1 & S2. 
Antipsychotics (APs), antiepileptic drugs (AEGs), cholinesterase inhibitors (ChEIs), dopamine agonists (DAGs), dopamine reuptake inhibitors (DRIs), gamma-aminobutyric acid (GABA)A 
receptor positive allosteric modulators (PAMs), monoamine oxidase inhibitors (MAOIs), muscarinic M1 agonists (M1 AGs), N-methyl-D-aspartate receptor antagonists (NMDA ANTs), 
noradrenergic and specific serotonergic antidepressants (NaSSAs), norepinephrine-dopamine disinhibitors (NDDIs), norepinephrine–dopamine reuptake inhibitors (NDRIs), norepinephrine 
reuptake inhibitors (NRIs), reversible inhibitors of monoamine oxidase A (RIMAs), serotonin antagonist and reuptake inhibitors (SARIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), 
selective serotonin reuptake enhancers (SSREs), selective serotonin reuptake inhibitors (SSRIs). 
Antidepressants Complex Mechanism  Author 
Agomelatine I, IV NDDI Gupta 2014 85, Kumar 2015 86, Singh 2015 170, de Mello 2015 84 
Amitriptyline I, IV NRI González-Pardo 2008 69, Hroudová 2010 16 
Bupropion I, IV NDRI Ferreira 2012 171 
Citalopram I, IV SSRI Hroudová 2010 16 
Desipramine I, IV NRI Hroudová 2010 16, Villa 2017 64 
Escitalopram I, IV SSRI Gonçalves 2012 59 
Fluoxetine I, IV SSRI Adzic 2013 60, Padilla 2011 62, Shumake 2010 63, Villa 2017 64 
Fluvoxamine I, IV SSRI Ferreira 2014 61 
Imipramine I, IV SNRI Abelaira 2011 172, Della 2012 173, Hroudová 2010 16, Ignácio 2015 174, Kumar 2010 68, Réus 2012 148 
Ketamine I, IV NMDA ANT Rezin 2009 175, Rezin 2010 94, Réus 2015 93, Venâncio 2015 95, de Oliveira 2011 92 
Mirtazapine I, IV NaSSA Hroudová 2010 16 
Moclobemide I, IV RIMA Hroudová 2010 16 
Nortriptyline I, IV NRI Scaini 2011 66 
Paroxetine I, IV SSRI Garabadu 2015 65, Scaini 2011 66 
Sertraline I, IV SSRI Gaur 2010 67, Kumar 2010 68, Sharma 2016 163 
Tianeptine I, IV SSRE Della 2012 173, Della 2013 176, Hroudová 2010 16 
Trazodone I, IV SARI Kumar 2010 68 
Venlafaxine I, IV SNRI Hroudová 2010 16, Kumar 2010 68, Scaini 2011 66, Sharma 2016 163 
Antipsychotics Complex Mechanism  Author 
Aripiprazole I, IV Atypical AP Scaini 2013 177, Streck 2007 104 
Chlorpromazine I, IV Typical AP Balijepalli 1999 98, Burkhardt 1993 101 
Clozapine I, IV Atypical AP Balijepalli 1999 98, Balijepalli 2001 99, Burkhardt 1993 101, Prince 1997 102, Prince 1998 103, Przedborski 1995 178, Scaini 2013 177, 
Streck 2007 104 
Fluphenazine I, IV Typical AP Balijepalli 1999 98, Prince 1997 102, Prince 1998 103 
Haloperidol I, IV Typical AP Balijepalli 1999 98, Balijepalli 2001 99, Barrientos 1998 100, Burkhardt 1993 101, Prince 1997 102, Prince 1998 103, Streck 2007 104 
Molindone I Typical AP Przedborski 1995 178 
Olanzapine I, IV Atypical AP Hroudová 2010 16, Scaini 2013 177, Streck 2007 104 
Quetiapine I, IV Atypical AP Ignácio 2015 174 
Risperidone I, IV Atypical AP Balijepalli 1999 98, Balijepalli 2001 99, Garabadu 2015 65 
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Thiothixene I, IV Typical AP Burkhardt 1993 101 
Anxiolytics Complex Mechanism  Author 
Clonazepam I, IV GABA-A PAM Mohamed 2013 179 
Diazepam I, IV GABA-A PAM Kumar 2014 132, van der Kooij 2018 180 
Mood stabilizers Complex Mechanism  Author 
Gabapentin I, IV AEG Kumar 2012 131, Kumar 2014 132 
Lamotrigine I, IV AEG Abelaira 2011 172, Kumar 2012 131 
Lithium I, IV Lithium Bachmann 2009 119, Feier 2013 120, Hroudová 2010 16, Kim 2016 121, Lambert 1999 122, Tan 2012 123, Valvassori 2010 124 
Topiramate I, IV AEG Kudin 2004 181 
Valproic acid I, IV AEG Bachmann 2009 119, Feier 2013 120, Hroudová 2010 16, Mishra 2014 140, Valvassori 2010 124 
Stimulants Complex Mechanism  Author 
Amphetamine I DRI Tan 2012 123 
Mazindol I, IV DRI Gonçalves 2014 138 
Methamphetamine I, IV DRI Brown 2005 135, Killinger 2014 139, Thrash 2010 141, Thrash-Williams 2013 142, Thrash-Williams 2016 143 
Methylphenidate I, IV DRI Fagundes 2007 136, Fagundes 2010 137 
Antidementia  Complex Mechanism  Author 
7-MEOTA I, IV Unknown Singh 2017 149 
Donepezil I, IV ChEI Singh 2015 170, Singh 2017 149 
Galantamine I, IV ChEI Singh 2015b 87, Singh 2017 149 
Latrepirdine I, IV Unknown Singh 2017 149 
Memantine I, IV NMDA ANT Kumar 2016 147, Réus 2012 148, Singh 2017 149 
Piracetam I, IV Unknown Singh 2017 149 
Rivastigmine I, IV ChEI Kumar 2009 182, Singh 2017 149 
Antiparkinsonian  Complex Mechanism  Author 
Amantadine I Unknown Thrash-Williams 2013 142 
Bromocriptine I DAG Przedborski 1995 178 
Levodopa I, IV DAG Abdin 2008 160, Calabrese 2007 161, Dixit 2013 159, Przedborski 1993 162, Sharma 2016 163 
Minocycline I Unknown Dixit 2013 159 
Pergolide I DAG Przedborski 1995 178 
Selegiline I, IV MAOI Czerniczyniec 2006 164, Przedborski 1995 178, Saravanan 2006 183 
Trihexyphenidyl I M1 AG Przedborski 1995 178 
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Tab. 2. Heterogeneity and Inconsistency. Significant Q statistics indicate the existence of 
heterogeneity. A I
2 
value of 0% indicates no observed inconsistency, whereas larger values shows 
increasing inconsistency. Egger's regression test for publication bias. The existence of potential 
publication bias is indicated by p-values < 005. df = degrees of freedom.   
Heterogeneity and Inconsistency 
  Q p-value I
2
 (%) 
Complex I Antidepressants 68200 0000 86% 
Antipsychotics 53387 0000 87% 
Anxiolytics 3499 0000 89% 
Mood stabilizers 13109 0000 85% 
Stimulants 4593 0434 11% 
Antidementia drugs 12233 0000 71% 
Antiparkinsonian drugs 8339 0000 84% 
Complex IV Antidepressants 70735 0000 71% 
Antipsychotics 66147 0000 76% 
Anxiolytics 457 0102 87% 
Mood stabilizers 33963 0000 80% 
Stimulants 11171 0000 53% 
Antidementia drugs 5739 0000 63% 
Antiparkinsonian drugs 558 0589 34% 
Egger's regression  
  z-value df p-value 
Complex I Antidepressants 174 22 0095 
Antipsychotics -136 8 0211 
Anxiolytics 049 2 0671 
Mood stabilizers 154 8 0161 
Stimulants -013 7 0902 
Antidementia drugs -116 4 0311 
Antiparkinsonian drugs 123 7 0258 
Complex IV Antidepressants 044 24 0665 
Antipsychotics 023 7 0822 
Anxiolytics 373 1 0167 
Mood stabilizers 110 8 0302 
Stimulants 064 4 0558 
Antidementia drugs -007 3 0949 
Antiparkinsonian drugs 097 1 0511 
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